Mcp (Metoclopramide Hydrochloride)

Metoclopramide acts on the dopaminergic pathway to provide antiemetic and gastro‑prokinetic effects.

• Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone.
• Gastroparesis: enhances gastric motility and accelerates stomach emptying, relieving related symptoms.
• Gastro‑oesophageal reflux disease (GERD): improves esophageal clearance and reduces reflux episodes.

• Metoclopramide antagonizes dopamine D2 receptors in the chemoreceptor trigger zone, diminishing the vomiting reflex. It also blocks peripheral D2 receptors, which increases acetylcholine release in the gastrointestinal tract, thereby enhancing smooth‑muscle contractility and promoting gastric emptying and intestinal transit.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Drowsiness
• Fatigue
• Restlessness or akathisia
• Diarrhea
• Dry mouth
• Headache

Serious or Rare Side Effects

• Extrapyramidal symptoms such as dystonia or severe akathisia
• Tardive dyskinesia with long‑term use
• Neuroleptic malignant syndrome
• Depression or suicidal ideation
• Severe allergic reactions including anaphylaxis
• Hyperprolactinemia leading to galactorrhea or menstrual disturbances

Before prescribing Metoclopramide, clinicians should consider several safety measures.

• Assess renal and hepatic function: dose adjustment may be required in impairment.
• Monitor for movement disorders: watch for signs of dystonia or tardive dyskinesia.
• Use cautiously in patients with depression or a history of suicidal thoughts.
• Avoid in individuals with known hypersensitivity to metoclopramide or other dopamine antagonists.
• Review concomitant medications that may increase central nervous system depression.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Metoclopramide can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid)

• CNS depressants (e.g., opioids, benzodiazepines) – may increase sedation and respiratory depression.
• Anticholinergic agents – can diminish the pro‑kinetic effect of metoclopramide.
• MAO inhibitors – risk of hypertensive crisis.
• CYP2D6 inhibitors – may raise metoclopramide plasma concentrations.
• QT‑prolonging drugs – additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs) – potential for serotonin syndrome.
• Other antiemetics – overlapping side‑effect profiles.
• Antipsychotics – additive dopamine antagonism may enhance extrapyramidal risk.
• Diuretics – possible electrolyte disturbances.
• Alcohol – may intensify central nervous system effects.